ClinConnect ClinConnect Logo
Search / Trial NCT04147637

FreeStyle Libre Plus Bluetooth Transmitter Adjunct: Can This Improve Glucose Accuracy and Reduce Burden of Hypoglycaemia

Launched by DASMAN DIABETES INSTITUTE · Oct 30, 2019

Trial Information

Current as of April 27, 2025

Withdrawn

Keywords

Hytpoglycemia Free Style Libre Flash Glucose Monitoring Miao Miao Time In Range

ClinConnect Summary

Study design:

Open-label, crossover, single center, randomized controlled trial of FreeStyle Libre with MiaoMiao Bluetooth transmitter adjunct with calibrations (FSL-M) compared to FreeStyle Libre alone (FSL-A) in people with T1DM.

Protocol summary:

Following informed written consent, subjects will be randomized to either FSL-M group using FSL with Miaomio and Tomato App premium version, or FSL-A with Libre Link app (stage 1). Subjects will spend 8 weeks in the assigned group followed by 2 weeks washout then subjects will switch over to the other group for further 8 weeks (stage 2).

Whi...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. T1DM for 12 months or more
  • 2. Age \>21 years old
  • 3. Established user of FreeStyle Libre for ≥3 months
  • 4. HbA1C \<12% (108mmol/mol)
  • 5. Able to check glucose with finger prick several times a day
  • Exclusion Criteria:
  • 1. Pregnancy or plans for pregnancy over the duration of the study
  • 2. Breast feeding
  • 3. Renal impairment with eGFR \<30ml/minute/1.73m2
  • 4. Significant anaemia (males Hb\<110g/L, females Hb \<100g/L)
  • 5. Active malignancy
  • 6. Significant vision impairment
  • 7. Any significant illness- decision will be made by the PI or Co-I
  • 8. Not able to attend study visits
  • 9. Not able or not willing to participate in all study components
  • 10. Not able or not willing to give written informed consent

About Dasman Diabetes Institute

Dasman Diabetes Institute (DDI) is a leading research and clinical organization dedicated to advancing diabetes care and management through innovative research, education, and community outreach. Established to address the growing prevalence of diabetes, DDI focuses on conducting high-quality clinical trials aimed at developing effective prevention and treatment strategies. The institute collaborates with local and international partners to enhance understanding of diabetes and its complications, fostering a multidisciplinary approach that integrates clinical practice with cutting-edge research. With a commitment to improving patient outcomes, DDI serves as a vital resource for healthcare professionals, researchers, and individuals affected by diabetes.

Locations

Kuwait City, , Kuwait

Patients applied

0 patients applied

Trial Officials

Ali Aldibbiat, MD PhD FRCP

Principal Investigator

Dasman Diabetes Institute

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials